1429324-21-9

Basic information

• Product Name: C₂₇H₂₉N₇O₅S
• Synonyms: C₂₇H₂₉N₇O₅S
• CAS NO: 1429324-21-9
• Molecular Weight: 563.637
• Mol File: 1429324-21-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₇H₂₉N₇O₅S(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₇H₂₉N₇O₅S(1429324-21-9)
• EPA Substance Registry System: C₂₇H₂₉N₇O₅S(1429324-21-9)

Safety Data

• Hazardous Substances Data: 1429324-21-9(Hazardous Substances Data)

Upstream product

• 960613-96-1 3-bromo-5-chloro-pyrazolo[1,5-a]pyrimidine 
• 1429324-16-2 C₂₃H₂₃N₇O₄S 
• 141-75-3 butyryl chloride 
• 1429324-15-1 C₃₃H₃₉N₇O₈S 
• 1429324-14-0 C₃₃H₄₁N₇O₉S 
• 1429324-13-9 C₃₉H₅₅N₇O₉SSi 
• 1429324-12-8 C₃₃H₅₂N₆O₅Si 
• 1429313-21-2 tert-butyl N-(3-bromopyrazolo[1,5-a]pyrimidin-5-yl)-N-[2-[tert-butoxycarbonyl-[2-(tert-butyl(dimethyl)silyl)oxyethyl]amino]ethyl]carbamate 
• 1429313-20-1 tert-butyl N-[2-[(3-bromopyrazolo[1,5-a]pyrimidin-5-yl)amino]ethyl]-N-[2-[tert-butyl(dimethyl)silyl]oxyethyl]carbamate 

Relevant articles and documents

MACROCYCLIC LRRK2 KINASE INHIBITORS

The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease